The #PanNASH Initiative aims to contribute to a better understanding and management of NASH, thus improving the lives of millions of patients worldwide
Joined May 2020
- Tweets594
- Following932
- Followers1.4K
- Likes181
Pinned Tweet
Lanifibranor, the pan-PPAR agonist, shines in preclinical models of chronic #liverdisease—elevating #vascular function, reducing portal #hypertension & showcasing improvements in #hepatic #enzymes & #inflammation
#Lanifibranor #PPAR #LiverHealth
1
606
Welcoming you into the new year with warm wishes for a blessed 2024 ahead! We look forward to continuously involving you in #PanNASH initiative, stay tuned for exciting updates. 🎇🎉
🖇️ ow.ly/SmWT50QhiYU
#LiverTwitter
1
442
NASH: The study employed #machinelearning with GBM to develop diagnostic models from histologically characterized data, identify patterns, & create predictive models that can be used in clinical trials & NASH biomarkers to help stratify at-risk patients.
🔗ow.ly/271y50QhhLG
271
T1DM & #NAFLD present a intricate relationship that increases the risk of more severe MAFLD subtypes & vascular complications. This study investigates if two insulin administration modalities- MDI & CSII- are associated with MAFLD in adults with T1DM.
🔗ow.ly/23SI50QhhGH
1
137
Did you know that higher levels of #alanine, #histidine, & #tyrosine have been linked to #NAFLD severity in both men & women, while different metabolic signatures were associated with the progression of the disease in men?
Read more - ow.ly/fZNF50QhhzN
#LiverTwitter
2
89
NAFLD is a major global disease, affecting 1 in 3 adults & 10% of children/adolescents. This article aims to summarise the NAFLD-centred discussions & research priorities highlighted by experts during the International Precision Medicine Forum.
🔗ow.ly/e95l50QhhvX
52
Transplant patients: 1/3 may develop obesity within a few years! Studies have shown that metabolic syndrome after transplantation may lead to MAFLD, a condition that causes graft dysfunction & fibrosis.
🖇️ ow.ly/h8QM50Qhhom
#LiverTwitter
78
#CMS, a risk factor for #NAFLD, is a multi-faceted condition. Research is needed into biomarkers, treatments, & ethnic/socioeconomic/environmental factors to gain better understanding & develop more effective treatments.
🔗ow.ly/pmJ350QfmYn
#LiverTwitter
63
💭Which non-invasive tool (#NIT) do you think shows the most promise in accurately detecting #liverfibrosis in #NAFLD patients with #T2DM?
Read more 👉 pannash.org/are-non-invasive…
#livertwitter
50%VCTE
0%NAFLD Fibrosis Score(NFS)
50%FIB-4
0%FM & FMVCTE
2 votes • Final results 68
Quantifying mortality risks in #NAFLD: Insights from a meta-analysis. Learn how elevated liver stiffness measurements are linked to a higher risk of all-cause mortality.
Read more 👉 ow.ly/HsGT50QbOUc
#LiverFibrosis #HealthResearch #LiverTwitter
61
🔬#NAFLD & pancreatic steatosis bidirectional relationship unveiled. A meta-analysis reveals significant associations & underscores the importance of understanding the liver-pancreas connection.
🔗 ow.ly/Zj6U50QbOTc
#MedicalResearch #MetabolicHealth #Pancreas #LiverTwitter
79
Key highlights from AASLD! Prof. Wong showcased the latest advances in #MASLD research.
#Lanifibranor, a pan-#PPAR agonist, with its potential to improve glucose levels. Dive into the discussion on advancements & side effects.
#LiverTwitter #NASH
1
2
192
Dive into NAFLD diagnosis dynamics with Dr. Guillaume Grzych. Uncover the importance of diverse #biomarkers & interdisciplinary collaboration.
🔗 ow.ly/BtEh50Qabmi
#NAFLD #LiverHealth #Fibrosis
64
Unveiling the ongoing global metabolic disease challenge: Insights from GBD data. #T2DM, #hypertension, #hyperlipidaemia, #obesity, & #NAFLD show increasing prevalence worldwide.
Learn more ➡️ ow.ly/PJIf50Q7MEF
#LiverTwitter #LiverHealth
82
🔬Enhancing #NASH trial success: Addressing comorbidities like #hypertension & #diabetes. Discover how addressing comorbid conditions like high blood pressure, #obesity, & type 2 diabetes can enhance the success of therapeutic trials.
Read more 👉ow.ly/4tsh50Q7MyZ
79
Exploring #NASH treatment: Progress in targeting #inflammation & #fibrosis in Phase III trials. Learn about the agents paving the way to #liverhealth. ow.ly/jNz250Q7Mse
#LiverTwitter
1
77
We are at #TLM23! Discussions highlight the evolving landscape with the new #nomenclature for #NASH = #MASLD. From fibrosis assessment to adolescent care, 8 KOLs are unraveling key questions.
#PanNASH #LiverHealth #TLMdX
1
122
PanNASH Initiative retweeted
#TLM2023 will start in 2 days! The @AASLDtweets MASLD SIG is pleased to share this MASLD program for your quick reference. See you in Boston soon!
Nurturing healthy livers: Investigating #mitochondria 's critical role in #fattyliver disease progression. This study explores the nuanced variations in hepatic mitochondrial function across diverse fatty liver diseases.
🔗 ow.ly/FXMe50Q4pfB
#LiverTwitter
62